Immunotherapy and its research progress of metastatic castration resistant prostate cancer / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 637-640, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-869718
ABSTRACT
The ideal immunotherapy should be highly lethal to the tumor and harmless to the body, therefore it’s applied to the highly fatal metastatic castration-resistant prostate cancer. Immunotherapy for prostate cancer currently includes vaccine therapy, immunocheckpoint blocking therapy, immunomodulator therapy, and combination therapy, which treat prostate cancer through different immune mechanisms. A vaccine called Sipuleucel-T has been approved by the Food and Drug Administration to treat metastatic castration-resistant prostate cancer, while research on other immune drugs is ongoing. This article reviews the current status and recent progress of various immunotherapies for metastatic castration-resistant prostate cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Urology
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS